Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Siegfried Holding AGXSWX:SFZN +0.07%89 EV-to-EBITDA is 10.35 as of Aug. 02, 2026, which is 22% below its 10-year median of 13.26. GuruFocus rates XSWX:SFZN with a GF Score™ of 89/100 and a GF Value™ of CHF92.61 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 747 Drug Manufacturers companies, Siegfried Holding AG ranks better than 60.37% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Siegfried Holding AG's enterprise value is CHF3,214 Mil.
Siegfried Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF311 Mil. Therefore, Siegfried Holding AG's EV-to-EBITDA for today is 10.35.
The historical rank and industry rank for Siegfried Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:SFZN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.35 Med: 13.26 Max: 29.41
Current: 10.35
During the past 13 years, the highest EV-to-EBITDA of Siegfried Holding AG was 29.41. The lowest was 8.35. And the median was 13.26.
XSWX:SFZN's EV-to-EBITDA is ranked better than 60.37% of 747
companies
in the Drug Manufacturers industry
Industry Median: 12.88
vs XSWX:SFZN: 10.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Siegfried Holding AG (XSWX:SFZN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Siegfried Holding AG's PE Ratio (TTM) for today is calculated as:
Siegfried Holding AG's share price for today is CHF75.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Siegfried Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF3.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Siegfried Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SFZN vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Siegfried Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siegfried Holding AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Siegfried Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Siegfried Holding AG's EV-to-EBITDA falls into.
Siegfried Holding AG's current Enterprise Value is CHF3,214 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Siegfried Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF311 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siegfried Holding AG (XSWX:SFZN) has a EV-to-EBITDA of 10.35 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Siegfried Holding AG. This is 22% below median its historical median of 13.26. Over the past decade, Siegfried Holding AG's EV-to-EBITDA has ranged from 8.35 to 29.41. According to the industry distribution chart, Siegfried Holding AG ranks #296 out of 747 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Siegfried Holding AG's EV-to-EBITDA too high?
Siegfried Holding AG's current EV-to-EBITDA of 10.35 is 22% below median its 10-year median of 13.26. Over the past 10 years, this metric has ranged from a low of 8.35 to a high of 29.41. The Drug Manufacturers industry median EV-to-EBITDA is 12.88. Siegfried Holding AG's value of 10.35 is 19.6% below this industry median. Based on the distribution chart, Siegfried Holding AG ranks #296 out of 747 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Siegfried Holding AG has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Siegfried Holding AG's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Siegfried Holding AG ranks #296 out of 747 companies for EV-to-EBITDA. This puts Siegfried Holding AG in the upper half of its industry. The industry median EV-to-EBITDA is 12.88. Siegfried Holding AG's value of 10.35 is 19.6% below this benchmark. Historically, Siegfried Holding AG's own EV-to-EBITDA has ranged from 8.35 to 29.41 over the past decade. While the company's 10-year median is 13.26 vs. the industry median of 12.88, Siegfried Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.88, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siegfried Holding AG's current EV-to-EBITDA of 10.35 is 19.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Siegfried Holding AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siegfried Holding AG's current EV-to-EBITDA is 10.35, which is 22% below median its own 10-year median of 13.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siegfried Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Siegfried Holding AG (XSWX:SFZN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF92.61, compared to a current price of CHF75.75 — trading 18.2% below its estimated fair value. The current EV-to-EBITDA is 10.35, which is 22% below median its 10-year median of 13.26 and 19.6% below the Drug Manufacturers industry median of 12.88. Siegfried Holding AG's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Siegfried Holding AG (XSWX:SFZN), the current EV-to-EBITDA is 10.35 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siegfried Holding AG (XSWX:SFZN) Overvalued in 2026?
Based on GuruFocus' analysis, Siegfried Holding AG stock appears to be undervalued.
The current stock price of CHF75.75 is trading 18.2% below its estimated GF Value™ of CHF92.61.
GuruFocus considers Siegfried Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:SFZN:
EV-to-EBITDA: 10.35 (22% below median its 10-year median of 13.26)
GF Value™: CHF92.61 vs. price of CHF75.75 (18.2% below fair value)
Industry Position: 19.6% below the Drug Manufacturers median (#296 of 747)
No single metric tells the full story. See the XSWX:SFZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
89GF Score
Get the complete analysis for XSWX:SFZN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SFZN has been successfully added to your 
